The planned bonds are expected to have a call option after 10 years. Fitch Ratings anticipates Dai-ichi Life's financial ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

Dai ichi Life Insurance Company Ltd decreased its holdings in Amazon.com, Inc. (NASDAQ:AMZN) by 13.6% during the 3rd quarter, ...

Dai-ichi Life Insurance Co. lost about ¥140 billion ... year and would be “more restrained” in the second half, the company’s president, Toshiaki Sumino, said in an interview.

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

It's the end of the road for the South San Francisco-based company, which became part of the Daiichi Sankyo in a $935 million deal in 2011 and since then has contributed two approved cancer ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope: Tokyo Wednesday, January 15, 2025, 09:00 Hrs [IST] Daiichi Sankyo Com ...

Dai-ichi Life Insurance Co. has reported a significant financial setback, incurring a loss of approximately ¥140 billion ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...